[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516601":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":36,"responsibleParty":69,"collaborators":71,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":25,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"State University of New York - Upstate Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CognilumTM","EXPERIMENTAL","During the study participants will be wear the transcranial photobiomodulation device Cognilum. The device will administer the stimulation of near infrared light (830nm) to specific areas of the child's brain.",[13],"Device: Cognilum TM: Light Treatment Condition",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham control","SHAM_COMPARATOR","During the study participants will wear the transcranial photobiomodulation device. The device will not be turned on and therefore no brain stimulation with near infrared light (830nm) will be provided.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Cognilum TM: Light Treatment Condition","The children will wear the CognilumTM device for approximately 10 minutes at a time, twice a week, for a period of 10 weeks.",[9,15],null,[27,32],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"William E Sullivan, PhD","CONTACT","315-464-3932","sullivaw@upstate.edu",{"name":33,"role":29,"phone":34,"phoneExt":25,"email":35},"Henry S Roane, PhD","315-464-3555","roaneh@upstate.edu",[37,58],{"facility":38,"status":39,"city":40,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Mt. Sinai Medical Center","RECRUITING","New York","10029","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-74.00597,40.71427,{"lat":48,"lon":47},[51,55],{"name":52,"role":29,"phone":53,"phoneExt":25,"email":54},"Alexander Kolevzon, MD","212-659-8752","alexander.kolevzon@mssm.edu",{"name":56,"role":29,"phone":25,"phoneExt":25,"email":57},"Catherine Sancimino, PhD","catherine.sancimino@mssm.edu",{"facility":59,"status":39,"city":60,"state":40,"zip":61,"country":42,"countryCode":43,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Golisano Center for Special Needs","Syracuse","13210",{"type":45,"coordinates":63},[64,65],-76.14742,43.04812,{"lat":65,"lon":64},[68],{"name":33,"role":29,"phone":34,"phoneExt":25,"email":35},{"type":70,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[72,75,78],{"name":73,"class":74},"JelikaLite LLC","INDUSTRY",{"name":76,"class":77},"Mt. Sinai School of Medicine, New York, New York","UNKNOWN",{"name":79,"class":77},"MetroEHS","100516601","integrated-platform-for-measuring-and-reducing-symptoms-of-autism-spectrum-disorder-100516601",false,"NCT06006637","Integrated Platform for Measuring and Reducing Symptoms of Autism Spectrum Disorder","IPMR ASD","Inclusion Criteria:\n\n* Ages 2 - 8\n* Autism spectrum disorder diagnosis\n* CARS-2 score of 30 - 45\n\nExclusion Criteria:\n\n* CARS scores less than 30 or over 45.\n* Taking psychotropic medications.\n* Having skin lesions on scalp\n* Having history of seizures\n* Having history of abnormal EEG\n* Being a relative of the PI or a researcher\n* Having implanted devices (including cochlear implants).","ALL","2 Years","8 Years",{"count":91,"type":92},80,"ESTIMATED","INTERVENTIONAL",[95],"NA","This study will consist of a randomized, double-blind, sham-controlled clinical trial at SUNY Upstate Medical University and Mt. Sinai Medical Center with 80 autistic children evaluating the effects of transcranial photobiomodulation (tPBM) on multiple clinically validated scales.",[98],"Autism Spectrum Disorder",[100,98],"Transcranial photobiomodulation","2025-10-10",{"date":103,"type":104},"2025-10-14","ACTUAL",{"date":106,"type":104},"2023-10-17",{"date":108,"type":92},"2026-08-15",{"name":5,"class":6},2]